Alx Oncology Holdings Inc Financials
This page shows Alx Oncology Holdings Inc (ALXO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
ALX’s dominant mechanic is a capital-consuming development model: lower R&D is shrinking annual losses while the balance-sheet cushion thins.
In FY2025, R&D spending was$77.0M against an operating loss of$104.0M , showing that losses remain tied largely to operating investment rather than heavy capital spending. Operating cash flow of-$84.1M nearly matched free cash flow of-$84.4M , so capital expenditures had little effect on the cash-consumption profile.
Operating losses narrowed from
By FY2025, total assets had fallen sharply from FY2023 levels to
Financial Health Signals
Alx Oncology Holdings Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Alx Oncology Holdings Inc passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Alx Oncology Holdings Inc reported a net loss of $101.7M while operations used $84.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Alx Oncology Holdings Inc reported an operating loss of $104.0M against $1.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Alx Oncology Holdings Inc's EBITDA was -$103.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 27.0% from the prior year.
Alx Oncology Holdings Inc reported -$101.7M in net income in fiscal year 2025. This represents an increase of 24.6% from the prior year.
Alx Oncology Holdings Inc earned -$1.90 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Alx Oncology Holdings Inc recorded an outflow of $84.4M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 31.1% from the prior year.
Alx Oncology Holdings Inc held $16.4M in cash against $4.5M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Alx Oncology Holdings Inc's ROE was -391.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 272.7 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Alx Oncology Holdings Inc invested $77.0M in research and development in fiscal year 2025. This represents a decrease of 33.8% from the prior year.
Alx Oncology Holdings Inc invested $212K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 52.6% from the prior year.
Not reported for fiscal year 2025.
ALXO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $0 | $0-100.0% | $1.2M-75.4% | $4.8M+132.0% | $2.1M |
| R&D Expenses | N/A | $77.0M-33.8% | $116.4M-17.9% | $141.8M+44.1% | $98.4M+63.5% | $60.2M+107.8% | $29.0M+77.6% | $16.3M+44.7% | $11.3M |
| SG&A Expenses | N/A | $23.9M-8.6% | $26.1M-8.4% | $28.5M-1.9% | $29.0M+24.2% | $23.4M+57.9% | $14.8M+347.0% | $3.3M+27.4% | $2.6M |
| Operating Income | N/A | -$104.0M+27.0% | -$142.5M+16.3% | -$170.3M-33.6% | -$127.4M-52.5% | -$83.6M-91.4% | -$43.7M-127.6% | -$19.2M-40.2% | -$13.7M |
| Interest Expense | N/A | $1.6M-7.3% | $1.7M+10.5% | $1.6M+557.6% | $238K+1730.8% | $13K | N/A | N/A | N/A |
| Income Tax | N/A | $0 | $0 | $0-100.0% | $64K+404.8% | -$21K-108.7% | $241K+608.8% | $34K-24.4% | $45K |
| Net Income | N/A | -$101.7M+24.6% | -$134.8M+16.1% | -$160.8M-30.2% | -$123.5M-47.9% | -$83.5M-82.5% | -$45.7M-137.7% | -$19.2M-40.1% | -$13.7M |
| EPS (Diluted) | — | -$1.90 | -$2.58+31.0% | -$3.74-23.4% | -$3.03-46.4% | -$2.07 | -$2.76 | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ALXO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $59.0M-60.0% | $147.8M-39.1% | $242.6M-20.9% | $306.5M-19.4% | $380.2M-12.8% | $436.1M+3984.4% | $10.7M | N/A |
| Current Assets | $50.7M-62.2% | $134.4M-28.8% | $188.7M-30.4% | $271.0M-26.2% | $367.0M-15.8% | $436.0M+4344.8% | $9.8M | N/A |
| Cash & Equivalents | $16.4M-6.8% | $17.6M-21.6% | $22.4M-54.1% | $48.8M-86.6% | $363.7M-16.2% | $434.2M+4715.6% | $9.0M+9.1% | $8.3M |
| Total Liabilities | $33.1M-3.2% | $34.2M-35.4% | $52.8M+22.8% | $43.0M+151.1% | $17.1M+176.0% | $6.2M-92.4% | $81.3M | N/A |
| Current Liabilities | $24.6M+32.7% | $18.5M-48.6% | $36.0M+27.1% | $28.3M+85.2% | $15.3M+146.5% | $6.2M+24.5% | $5.0M | N/A |
| Long-Term Debt | $4.5M-52.1% | $9.5M-1.8% | $9.6M+2.7% | $9.4M | N/A | N/A | $5.4M | N/A |
| Total Equity | $26.0M-77.1% | $113.6M-40.1% | $189.7M-28.0% | $263.5M-27.4% | $363.0M-15.5% | $429.8M+708.5% | -$70.6M-36.4% | -$51.8M |
| Retained Earnings | -$722.8M-16.4% | -$621.1M-27.7% | -$486.3M-49.4% | -$325.5M-61.1% | -$202.0M-70.4% | -$118.5M-62.8% | -$72.8M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
ALXO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$70.8M | -$84.1M+31.0% | -$121.9M+6.5% | -$130.4M-46.1% | -$89.2M-31.0% | -$68.1M-77.9% | -$38.3M-168.7% | -$14.2M-8.0% | -$13.2M |
| Capital Expenditures | $172K | $212K-52.6% | $447K-64.9% | $1.3M-10.7% | $1.4M+114.3% | $666K+2048.4% | $31K-91.2% | $353K-45.9% | $653K |
| Free Cash Flow | -$71.0M | -$84.4M+31.1% | -$122.4M+7.0% | -$131.6M-45.2% | -$90.7M-31.8% | -$68.8M-79.5% | -$38.3M-162.4% | -$14.6M-5.5% | -$13.8M |
| Investing Cash Flow | -$65.9M | $82.6M-4.3% | $86.3M+93.2% | $44.7M+119.0% | -$235.4M-4682.0% | -$4.9M-907.0% | $610K+272.8% | -$353K+45.9% | -$653K |
| Financing Cash Flow | $140.3M | $362K-98.8% | $30.8M-48.0% | $59.3M+501.3% | $9.9M+298.9% | $2.5M-99.5% | $462.9M+2914.1% | $15.4M+1535600.0% | $1K |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $6K |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ALXO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | N/A | -3694.0% | -400.0% | -662.0% |
| Net Margin | N/A | N/A | N/A | N/A | N/A | -3869.7% | -401.2% | -664.3% |
| Return on Equity | -391.4%-272.7pp | -118.7%-33.9pp | -84.8%-37.9pp | -46.9%-23.9pp | -23.0%-12.3pp | -10.6% | N/A | N/A |
| Return on Assets | -172.2%-81.0pp | -91.3%-24.9pp | -66.3%-26.0pp | -40.3%-18.3pp | -21.9%-11.5pp | -10.5%+169.8pp | -180.3% | N/A |
| Current Ratio | 2.07-5.2x | 7.26+2.0x | 5.24-4.3x | 9.57-14.4x | 24.00-46.3x | 70.28+68.3x | 1.97 | N/A |
| Debt-to-Equity | 0.17+0.1x | 0.080.0x | 0.050.0x | 0.040.0x | 0.050.0x | 0.01 | N/A | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | -3242.0% | -304.5% | -669.7% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Alx Oncology Holdings Inc Ranks
Frequently Asked Questions
Is Alx Oncology Holdings Inc profitable?
No, Alx Oncology Holdings Inc (ALXO) reported a net income of -$101.7M in fiscal year 2025.
What is Alx Oncology Holdings Inc's EBITDA?
Alx Oncology Holdings Inc (ALXO) had EBITDA of -$103.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Alx Oncology Holdings Inc have?
As of fiscal year 2025, Alx Oncology Holdings Inc (ALXO) had $16.4M in cash and equivalents against $4.5M in long-term debt.
What is Alx Oncology Holdings Inc's return on equity (ROE)?
Alx Oncology Holdings Inc (ALXO) has a return on equity of -391.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Alx Oncology Holdings Inc's free cash flow?
Alx Oncology Holdings Inc (ALXO) recorded an outflow of $84.4M in free cash flow during fiscal year 2025. This represents a 31.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Alx Oncology Holdings Inc's operating cash flow?
Alx Oncology Holdings Inc (ALXO) recorded an outflow of $84.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Alx Oncology Holdings Inc's total assets?
Alx Oncology Holdings Inc (ALXO) had $59.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Alx Oncology Holdings Inc's capital expenditures?
Alx Oncology Holdings Inc (ALXO) invested $212K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Alx Oncology Holdings Inc spend on research and development?
Alx Oncology Holdings Inc (ALXO) invested $77.0M in research and development during fiscal year 2025.
What is Alx Oncology Holdings Inc's current ratio?
Alx Oncology Holdings Inc (ALXO) had a current ratio of 2.07 as of fiscal year 2025, which is generally considered healthy.
What is Alx Oncology Holdings Inc's debt-to-equity ratio?
Alx Oncology Holdings Inc (ALXO) had a debt-to-equity ratio of 0.17 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Alx Oncology Holdings Inc's return on assets (ROA)?
Alx Oncology Holdings Inc (ALXO) had a return on assets of -172.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Alx Oncology Holdings Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Alx Oncology Holdings Inc (ALXO) held $48.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $84.1M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Alx Oncology Holdings Inc's Piotroski F-Score?
Alx Oncology Holdings Inc (ALXO) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Alx Oncology Holdings Inc's earnings high quality?
Alx Oncology Holdings Inc (ALXO) reported a net loss of $101.7M while operations used $84.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Alx Oncology Holdings Inc cover its interest payments?
Alx Oncology Holdings Inc (ALXO) reported an operating loss of $104.0M against $1.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.